neuropeptide NAP (TFA removed)

neuropeptide NAP (TFA removed)

• COA/MS/HPLC Report
• Handling and Storage of Synthetic Peptides
• Material Safety Data Sheets (MSDS)

Batch to batch variation of the purity

NAPVSIPQ

Asn-Ala-Pro-Val-Ser-Ile-Pro-Gln

8

98.1%

C₃₆H₆₀N₁₀O₁₂

824.44

Synthetic

Powder

Davunetide (AL-108, NAP) is the acetate salt of an eight aminoacid peptide (NAPVSIPQ) derived from activity dependent neuroprotective protein, a growth factor released from glia in response to exposure to vasoactive intestinal peptide. In preclinical studies, davunetide promoted microtubule stability and reduced tau phosphorylation. Because progressive supranuclear palsy (PSP) is linked to tau pathology, davunetide could be a treatment for PSP. We assessed the safety and effi cacy of davunetide in patients with PSP.

Normally, this peptide will be delivered in lyophilized form and should be stored in a freezer at or below -20 °C. For more details, please refer to the manual: Handling and Storage of Synthetic Peptides

• Greggio S, de Paula S, de Oliveira IM, Trindade C, Rosa RM, Henriques JA, DaCosta JC NAP prevents acute cerebral oxidative stress and protects against long-term brain injury and cognitive impairment in a model of neonatal hypoxia-ischemia Neurobiol Dis 2011 Oct;44(1):152-9.
• Magen I, Gozes I. Davunetide: Peptide therapeutic in neurological disorders. Curr Med Chem. 2014;21(23):2591-8. doi: 10.2174/0929867321666140217124945. PMID: 24533805.

Trifluoroacetic acid (TFA) has a significant impact on peptides due to its role in the peptide synthesis process.

TFA is essential for the protonation of peptides that lack basic amino acids such as Arginine (Arg), Histidine (His), and Lysine (Lys), or ones that have blocked N-termini. As a result, peptides often contain TFA salts in the final product.

TFA residues, when present in custom peptides, can cause unpredictable fluctuations in experimental data. At a nanomolar (nM) level, TFA can influence cell experiments, hindering cell growth at low concentrations (as low as 10 nM) and promoting it at higher doses (0.5–7.0 mM). It can also serve as an allosteric regulator on the GlyR of glycine receptors, thereby increasing receptor activity at lower glycine concentrations.

In an in vivo setting, TFA can trifluoroacetylate amino groups in proteins and phospholipids, inducing potentially unwanted antibody responses. Moreover, TFA can impact structure studies as it affects spectrum absorption.